High prevalence of acute exacerbation of interstitial lung disease in Japanese patients with systemic sclerosis

Tohoku Journal of Experimental Medicine

Volumn 239, Issue 4, 2016, Pages 279-305

  Tomiyama, Fumiko ^a   Watanabe, Ryu ^a   Ishii, Tomonori ^a   Kamogawa, Yukiko ^a   Fujita, Yoko ^a   Shirota, Yuko ^a   Sugimura, Koichiro ^a   Fujii, Hiroshi ^a   Harigae, Hideo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute exacerbation; Interstitial lung disease; Overlap; Polymyositis dermatomyositis; Systemic sclerosis

Indexed keywords

CALCINEURIN INHIBITOR; CENTROMERE ANTIBODY; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DERMATOMYOSITIS; DISEASE EXACERBATION; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; JAPANESE (CITIZEN); MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY RATE; POLYMYOSITIS; PREVALENCE; PROGNOSIS; SURVIVAL RATE; SYSTEMIC SCLEROSIS; ACUTE DISEASE; COMPLICATION; DEMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE COURSE; JAPAN; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; DEMOGRAPHY; DISEASE PROGRESSION; FEMALE; HUMANS; JAPAN; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; SCLERODERMA, SYSTEMIC; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 85006750253     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.239.297     Document Type: Article

References (46)

1. Aletaha, D., Neogi, T., Silman, A.J., Funovits, J., Felson, D.T., Bingham, C.O. III., Birnbaum, N.S., Burmester, G.R., Bykerk, V.P., Cohen, M.D., Combe, B., Costenbader, K.H., Dougados, M., Emery, P., Ferraccioli, G., et al. (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum., 62, 2569-2581.
2. Ando, K., Motojima, S., Doi, T., Nagaoka, T., Kaneko, N., Aoshima, M. & Takahashi, K. (2013) Effect of glucocorticoid monotherapy on pulmonary function and survival in Japanese patients with scleroderma-related interstitial lung disease. Respir. Investig., 51, 69-75.
3. Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., Sato, A. & Kudoh, S. (2005) Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 171, 1040-1047.
4. Bohan, A. & Peter, J.B. (1975) Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med., 292, 344-347.
5. Broen, J.C., Radstake, T.R. & Rossato, M. (2014) The role of genetics and epigenetics in the pathogenesis of systemic sclerosis. Nat. Rev. Rheumatol., 10, 671-681.
6. Bussone, G. & Mouthon, L. (2011) Interstitial lung disease in systemic sclerosis. Autoimmun. Rev., 10, 248-255.
7. Cappelli, S., Bellando-Randone, S., Camiciottoli, G., De Paulis, A., Guiducci, S. & Matucci-Cerinic, M. (2015) Interstitial lung disease in systemic sclerosis: where do we stand? Eur. Respir. Rev., 24, 411-419.
8. Clements, P.J., Hurwitz, E.L., Wong, W.K., Seibold, J.R., Mayes, M., White, B., Wigley, F., Weisman, M., Barr, W., Moreland, L., Medsger, T.A. Jr., Steen, V.D., Martin, R.W., Collier, D., Weinstein, A., et al. (2000) Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum., 43, 2445-2454.
9. Collard, H.R., Moore, B.B., Flaherty, K.R., Brown, K.K., Kaner, R.J., King, T.E. Jr., Lasky, J.A., Loyd, J.E., Noth, I., Olman, M.A., Raghu, G., Roman, J., Ryu, J.H., Zisman, D.A., Hunninghake, G.W., et al. (2007) Acute exacerbations of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 176, 636-643.
10. Czirjak, L., Kumanovics, G., Varju, C., Nagy, Z., Pakozdi, A., Szekanecz, Z. & Szucs, G. (2008) Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann. Rheum. Dis., 67, 59-63.
11. Fan, M.H., Feghali-Bostwick, C.A. & Silver, R.M. (2014) Update on scleroderma-associated interstitial lung disease. Curr. Opin. Rheumatol., 26, 630-636.
12. Ferri, C., Sebastiani, M., Lo Monaco, A., Iudici, M., Giuggioli, D., Furini, F., Manfredi, A., Cuomo, G., Spinella, A., Colaci, M., Govoni, M. & Valentini, G. (2014) Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients’ population and review of the literature. Autoimmun. Rev., 13, 1026-1034.
13. Fujibayashi, T., Sugai, S., Miyasaka, N., Hayashi, Y. & Tsubota, K. (2004) Revised Japanese criteria for Sjögren’s syndrome (1999): availability and validity. Mod. Rheumatol., 14, 425-434.
14. Furst, D.E., Clements, P.J., Steen, V.D., Medsger, T.A. Jr., Masi, A.T., D’Angelo, W.A., Lachenbruch, P.A., Grau, R.G. & Seibold, J.R. (1998) The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J. Rheumatol., 25, 84-88.
15. Gabrielli, A., Avvedimento, E.V. & Krieg, T. (2009) Scleroderma. N. Engl. J. Med., 360, 1989-2003.
16. Hashimoto, A., Endo, H., Kondo, H. & Hirohata, S. (2012) Clinical features of 405 Japanese patients with systemic sclerosis. Mod. Rheumatol., 22, 272-279.
17. Hashimoto, A., Tejima, S., Tono, T., Suzuki, M., Tanaka, S., Matsui, T., Tohma, S., Endo, H. & Hirohata, S. (2011) Predictors of survival and causes of death in Japanese patients with systemic sclerosis. J. Rheumatol., 38, 1931-1939.
18. Hunzelmann, N., Genth, E., Krieg, T., Lehmacher, W., Melchers, I., Meurer, M., Moinzadeh, P., Muller-Ladner, U., Pfeiffer, C., Riemekasten, G., Schulze-Lohoff, E., Sunderkoetter, C., Weber, M., Worm, M., Klaus, P., et al. (2008) The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford), 47, 1185-1192.
19. Ioannidis, J.P., Vlachoyiannopoulos, P.G., Haidich, A.B., Medsger, T.A. Jr., Lucas, M., Michet, C.J., Kuwana, M., Yasuoka, H., van den Hoogen, F., Te Boome, L., van Laar, J.M., Verbeet, N.L., Matucci-Cerinic, M., Georgountzos, A. & Moutsopoulos, H.M. (2005) Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am. J. Med., 118, 2-10.
20. Ishizuka, M., Watanabe, R., Ishii, T., Machiyama, T., Akita, K., Fujita, Y., Shirota, Y., Fujii, H. & Harigae, H. (2016) Longterm follow-up of 124 patients with polymyositis and dermatomyositis: Statistical analysis of prognostic factors. Mod. Rheumatol., 26, 115-120.
21. Jacobsen, S., Ullman, S., Shen, G.Q., Wiik, A. & Halberg, P. (2001) Influence of clinical features, serum antinuclear antibodies, and lung function on survival of patients with systemic sclerosis. J. Rheumatol., 28, 2454-2459.
22. Joseph, C.G., Darrah, E., Shah, A.A., Skora, A.D., Casciola-Rosen, L.A., Wigley, F.M., Boin, F., Fava, A., Thoburn, C., Kinde, I., Jiao, Y., Papadopoulous, N., Kinzler, K.W., Volgelstein, B. & Rosen, A. (2014) Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science, 343, 152-157.
23. Kaji, K., Fertig, N., Medsger, T.A. Jr., Satoh, T., Hoshino, K., Hamaguchi, Y., Hasegawa, M., Lucas, M., Schnure, A., Ogawa, F., Sato, S., Takehara, K., Fujimoto, M. & Kuwana, M. (2014) Autoantibodies to RubBL1 and Rub BL2: a novel systemic sclerosis-related antibody associated with diffuse cutaneous and skeletal muscle involvement. Arthritis Care Res., 66, 575-584.
24. Kanda, Y. (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant., 48, 452-458.
25. Kondoh, Y., Taniguchi, H., Kawabata, Y., Yokoi, T., Suzuki, K. & Takagi, K. (1993) Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathological findings in three cases. Chest, 103, 1808-1812.
26. Kowal-Bielecka, O., Landewe, R., Avouac, J., Chwiesko, S., Miniati, I., Czirjak, L., Clements, P., Denton, C., Farge, D., Fligelstone, K., Foldvari, I., Furst, D.E., Muller-Ladner, U., Seibold, J., Silver, R.M., et al. (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann. Rheum. Dis., 68, 620-628.
27. LeRoy, E.C., Black, C., Fleischmajer, R., Jablonska, S., Krieg, T., Medsger, T.A. Jr., Rowell, N. & Wollheim, F. (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol., 15, 202-205.
28. Mathai, S.C. & Danoff, S.K. (2016) Management of interstitial lung disease associated with connective tissue disease. BMJ, 352, h6819.
29. Meyer, O.C., Fertig, N., Lucas, M., Somogyi, N. & Medsger, T.A. Jr. (2007) Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J. Rheumatol., 34, 104-109.
30. Moinzadeh, P., Aberer, E., Ahmadi-Simab, K., Blank, N., Distler, J.H., Fierlbeck, G., Genth, E., Guenther, C., Hein, R., Henes, J., Herich, L., Herrgott, I., Koetter, I., Kreuter, A., Krieg, T., et al. (2015) Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Ann. Rheum. Dis., 74, 730-737.
31. Moinzadeh, P., Fonseca, C., Hellmich, M., Shah, A.A., Chighizola, C., Denton, C.P. & Ong, V.H. (2014) Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res. Ther., 16, R53.
32. Nihtyanova, S.I. & Denton, C.P. (2010) Autoantibodies as predictive tools in systemic sclerosis. Nat. Rev. Rheumatol., 6, 112-116.
33. Nihtyanova, S.I., Schreiber, B.E., Ong, V.H., Rosenberg, D., Moinzadeh, P., Coghlan, J.G., Wells, A.U. & Denton, C.P. (2014) Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheum., 66, 1625-1635.
34. Pakozdi, A., Nihtyanova, S., Moinzadeh, P., Ong, V.H., Black, C.M. & Denton, C.P. (2011) Clinical and serological hallmarks of systemic sclerosis overlap syndromes. J. Rheumatol., 38, 2406-2409.
35. Park, I.N., Kim, D.S., Shim, T.S., Lim, C.M., Lee, S.D., Koh, Y., Kim, W.S., Kim, W.D., Jang, S.J. & Colby, T.V. (2007) Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. Chest, 132, 214-220.
36. Ryerson, C.J., Cottin, V., Brown, K.K. & Collard, H.R. (2015) Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur. Repir. J., 46, 512-520.
37. Shirai, Y., Okazaki, Y., Inoue, Y., Tamura, Y., Yasuoka, H., Takeuchi, T. & Kuwana, M. (2015) Elevated levels of pentraxin 3 in systemic sclerosis: associations with vascular manifestations and defective vasculogenesis. Arthritis Rheumatol., 67, 498-507.
38. Steen, V.D. & Medsger, T.A. (2007) Changes in causes of death in systemic sclerosis, 1972-2002. Ann. Rheum. Dis., 66, 940-944.
39. Suda, T., Kaida, Y., Nakamura, Y., Enomoto, N., Fujisawa, T., Imokawa, S., Hashizume, H., Naito, T., Hashimoto, D., Takehara, Y., Inui, N., Nakamura, H., Colby, T.V. & Chida, K. (2009) Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. Respir. Med., 103, 846-853.
40. Tachikawa, R., Tomii, K., Ueda, H., Nagata, K., Nanjo, S., Sakurai, A., Otsuka, K., Kaji, R., Hayashi, M., Katakami, N. & Imai, Y. (2012) Clinical features and outcome of acute exacerbation of interstitial pneumonia: collagen vascular disease-related versus idiopathic. Respiration, 83, 20-27.
41. Tashkin, D.P., Elashoff, R., Clements, P.J., Goldin, J., Roth, M.D., Furst, D.E., Arriola, E., Silver, R., Strange, C., Bolster, M., Seibold, J.R., Riley, D.J., Hsu, V.M., Varga, J., Schraufnagel, D.E., et al. (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med., 354, 2655-2666.
42. Tashkin, D.P., Elashoff, R., Clements, P.J., Roth, M.D., Furst, D.E., Silver, R.M., Goldin, J., Arriola, E., Strange, C., Bolster, M., Seibold, J.R., Riley, D.J., Hsu, V.M., Varga, J., Schraufnagel, D.E., et al. (2007) Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am. J. Respir. Crit. Care Med., 176, 1026-1034.
43. van den Hoogen, F., Khanna, D., Fransen, J., Johnson, S.R., Baron, M., Tyndall, A., Matucci-Cerinic, M., Naden, R.P., Medsger, T.A. Jr., Carreira, P.E., Riemekasten, G., Clements, P.J., Denton, C.P., Distler, O., Allnore, Y., et al. (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum., 65, 2737-2747.
44. Wells, A.U. & Denton, C.P. (2014) Interstitial lung disease in connective tissue disease-mechanisms and management. Nat. Rev. Rheumatol., 10, 728-739.
45. Yasuoka, H. (2016) Recent treatments of interstitial lung disease with systemic sclerosis. Clin. Med. Insights Circ. Respir. Pulm. Med., 9, 97-110.
46. Yoshida, M., Watanabe, R., Ishii, T., Machiyama, T., Akita, K., Fujita, Y., Shirota, Y., Sugimura, K., Fujii, H., Shimokawa, H. & Harigae, H. (2016) Retrospective analysis of 95 patients with large vessel vasculitis: a single center experience. Int. J. Rheum. Dis., 19, 87-94.